ACR Best Abstracts - Day 2

Jack Cush, MD

Nov 13, 2022 6:22 pm

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a pic.twitter.com/kpXZbRSoMo
— Richard Conway (@RichardPAConway) November 13, 2022

Biologics to treat gut microbiome dysbiosis??
In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls.
Collinsella remained stable - possible biomarker?
Abs#1162 @RheumNow #ACR22 #ACRBest pic.twitter.com/vmQFJMpNPP
— Robert B Chao, MD (@doctorRBC) November 13, 2022

I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed

Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI

Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 pic.twitter.com/C6isdSn2eI
— Mike Putman (@EBRheum) November 13, 2022

#ACR22 Abstr#1464 Press Release #lupus. Should we worry of pts without nephritis & low grade proteinuria UPCR >0.2 & <0.5? A cohort study showed 50% progressed to =>0.5 at 2 yrs & 11% renal biopsy +ve. Important to monitor UPCR. Need biomarkers for this At-Risk @RheumNow #ACRBest pic.twitter.com/eOODUynvP4
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 13, 2022

Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest ⁦@RheumNow⁩ #ClinicalPearl pic.twitter.com/S8fHi7dFoD
— Janet Pope (@Janetbirdope) November 13, 2022

Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE@RheumNow #ACRBest pic.twitter.com/uamJe05odq
— Eric Dein (@ericdeinmd) November 13, 2022

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!

Stop RA: RCT HCQ vs. PBO in pts at-risk

Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%

Trial interrupted as met futility criteria.https://t.co/n31OmsjLhM

Abs#1604 #ACR22 @RheumNow #ACRBest pic.twitter.com/NVYS8kB5to
— Aurelie Najm (@AurelieRheumo) November 13, 2022

Excllent plenary, medication copay modifies treatment adherence in SLE

>$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%)

Easy to imagine that all our innovation cannot overcome access & barriers

Should be priority to fix#ACR22 @RheumNow #ACRBest Abstr#1115 pic.twitter.com/BPfr9mCVgy
— Mike Putman (@EBRheum) November 13, 2022